Annual revenue fell from KRW 461.2 billion in 2022 to KRW 429.4 billion in 2023 (down 6.9% year on year), then rose for two consecutive years from 2024 to 2025, to KRW 570.9 billion in 2024 (up 33.0% year on year) and KRW 616.1 billion in 2025 (up 7.9% year on year). 2025 is the largest year of the 2022-2025 period.
The company posted operating losses of KRW 45.2 billion in 2022, KRW 73.2 billion in 2023, KRW 54.4 billion in 2024 and KRW 73.3 billion in 2025, four straight years in the red, and its operating margin was at its worst in 2023 at -17.0%.
Net income attributable to controlling shareholders turned from a net loss of KRW 11.3 billion in 2022 to a profit of KRW 187.5 billion in 2023, and the sale of its subsidiary Solus Biotech that year (securing KRW 350.0 billion) may have affected the earnings structure.
Net income attributable to controlling shareholders in 2024 was KRW 4.64 billion, down 97.5%, and in 2025 it turned back to a loss, with a net loss attributable to controlling shareholders of KRW 66.9 billion.
Including non-controlling interests, the net loss for 2025 was KRW 138.4 billion, larger than on a controlling-shareholder basis. Operating cash flow was -KRW 190.0 billion in 2024 and -KRW 18.1 billion in 2025.
Quarterly revenue rose from KRW 145.1 billion in Q3 2025 to KRW 169.5 billion in Q4 2025 (up 16.8% quarter on quarter) and KRW 192.6 billion in Q1 2026 (up 13.6% quarter on quarter), but fell to KRW 125.5 billion in Q3 2026, down 13.5% year on year.
Operating losses continued every quarter from KRW 21.2 billion in Q3 2025 through KRW 30.1 billion in Q3 2026, with the largest being KRW 31.6 billion in Q2 2026.
The Q2 2026 net income attributable to controlling shareholders of KRW 43.3 billion was a profit despite an operating loss, so non-operating items and other factors are suspected to have contributed, and the breakdown must be confirmed in the periodic report.
In Q3 2026, the net loss attributable to controlling shareholders was KRW 57.6 billion, a return to a loss. The company cited higher electricity costs in Hungary and increased depreciation expenses as factors behind the Q3 earnings deterioration.